Professor Shlomo Ben-Haim is an entrepreneur in the field of medical technology with a long and successful record of exits. He is co-founder of a number of successful medical device and biomedical companies, covering the fields of cardiology, obesity, esthetics and cosmetics, anti-viral medications, deep vein thrombosis prevention, therapy for limb ischemia, and post-stroke and sports injuries rehabilitation. In addition to his significant expertise and experience within the medical device industry, Professor Ben-Haim has also been effective in developing and maximizing the value of his companies. Working with his partners, he oversaw the merger of 12 of the companies he co-founded with leading industry multinationals, in deals valued at over $1 billion in total, including the sale of sale of Biosense to Johnson & Johnson for $427 million.
With education in the fields of nuclear physics, mathematics, biophysics, philosophy and medicine, Professor Ben-Haim has held faculty appointments as a Professor of Medicine, Physiology and Biophysics at Harvard University and the Technion ‒ Israel Institute of Technology. He is the inventor of over 550 patents and patent applications worldwide, including a navigated cardiac catheterization system and an implantable device for treating diabetes and obesity. He has held a variety of executive roles and board positions in both start-up medical device companies and leading industry multinationals, serving as Chief Scientist at Johnson & Johnson’s Biosense Webster, and as Executive Chairman of Impulse Dynamics NV, MetaCure Limited, Spectrum Dynamics LLC, Motorika Limited, Core Dynamics Limited, FlowMedic Limited and Goji Ltd.
Professor Ben-Haim’s current focus is on building new business models in healthcare, which both improve patient health and reduce government spending. In addition to his activities in the medical device field, he is also an active philanthropist. He is a founding partner of Bridge to the Future, a charitable foundation dedicated to improving health and education in underserved communities, and a partner in Atidim, a philanthropic program committed to lowering social and financial gaps in society.